Anell, A. (2004), Priority setting for pharmaceuticals: the use of health economic evidence by reimbursement and clinical guidance committees, The European Journal of Health Economics, 5: 28–35.
Anell, A. and Persson, U. (2005), Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?, The European Journal of Health Economics, 50: 274–279.
Bell, J.A.Hyland, S.DePellegrin, T.Upshur, R.E.Bernstein, M., and Martin, D.K. (2004), SARS and hospital priority setting: a qualitative case study and evaluation, BMC Health Services Research, 4(1): 36.
Daniels, N. and Sabin, J.E. (1997), Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers, Philosophy and Public Affairs, 26(4): 302–350.
Daniels, N. and Sabin, J.E. (1998), The ethics of accountability in managed care reform, Health Affairs, 17(5): 50–64.
Daniels, N. and Sabin, J.E. (2002), Setting Limits Fairly: Can We Learn to Share Medical Resources? New York: Oxford University Press.
Daniels, N.Teagarden, J.R., and Sabin, J.E. (2003), An ethical template for pharmacy benefits: a way to encourage broader public learning and debate about setting limits fairly, Health Affairs, 22(1): 125–137.
Gibson, J.L.Martin, D.K., and Singer, P.A. (2005), Priority setting in hospitals: fairness, inclusiveness, and the problem of institutional power differences, Social Science of Medicine, 61(11): 2355–2362.
Ham, C.Robert, G.Martin, D.K., and Singer, P.A. (2003), Reasonable Rationing: International Experience of Priority Setting in Health Care, Philadelphia: Open University Press.
Henry, D. (1992), Economic analysis as an aid to sudsidisation decisions: the development of Australian guidelines for pharmaceuticals, PharmacoEconomics, 1(1): 54–67.
Hill, S.Garattini, S.van Loenhout, J.O’Brien, B., and de Joncheere, K. (2003), ‘Technology Appraisal Programme of the National Institute for Clinical Excellence: a review by WHO.
Holm, S. (1998), Goodbye to the simple solutions: the second phase of priority setting in health care, British Medical Journal, 317: 1000–1007.
Jansson, S. and Anell, A. (2005), ‘Subventionering av läkemedel – förutsättningar för öppna och legitima beslutsprocesser i Läkemedelsförmånsnämnden’ (Reimbursement of pharmaceuticals – conditions of explicit and legitimate decision making processes at the Pharmaceutical Benefits Board), Report 2005:1, The National Centre for Priority Setting in Health Care, http://e.lio.se/prioriteringscentrum, 2005-02-13.
Jansson, S. and Anell, A. (2006), The impact of decentralised drug-budgets in Sweden – a survey of physicians’ attitudes towards cost and cost-effectiveness, Health Policy, 76: 299–311.
Kapiriri, L.O.F.Norheim, Norheim,, and D.K.Martin, Martin, (2006), Priority setting at the micro-, meso- and macro-levels in Canada, Norway and Uganda, Health Policy (E-pub in head of publication).
Laupacis, A. (2006), Economic evaluations in the Canadian Common Drug Review, Pharmacoeconomics, 24(11): 1157–1162.
Liss, P.-E. (2004), ‘The usefulness of the need-principle in setting of priorities’, Paper presented at the 5th International Conference on Priorities in Health Care, 3–5 November, Wellington, New Zealand.
Madden, S.Martin, D.K.Downey, S., and Singer, P.A. (2005), Hospital priority setting with an appeals process: a qualitative case study and evaluation, Health Policy, 73(1): 10–20.
Martin, D.K.Pater,, J.L. and Singer, P.A. (2001), Priority setting decisions for new cancer drugs: what rationales are used?, Lancet, 358: 1676–1681.
Martin, D.K.Shulman, K.Santiago-Sorrell, P., and Singer, P. (2003a), Priority setting and hospital strategic planning: a qualitative case study, Journal of Health Services and Research Policy, 8(4): 197–201.
Martin, D.K.Walton, N., and Singer, P. (2003b), Priority setting in surgery: improve the process and share the learning, World Journal of Surgery, 27(8): 962–966.
McMahon, M.Morgan, S., and Mitton, C. (2006), The common drug review: a NICE start for Canada?, Health Policy, 77: 339–351.
Ministry of Health and Social Affairs (2000), Den nyaläkemedelsförmånen, Betänkande av utredningen om läkemedelsförmånen. (The new pharmaceutical benefit system), SOU: 86.
Mitton, C.R.McMahon, M.Morgan, S., and Gibson, J. (2006), Centralized drug review processes: are they fair?, Social Science and Medicine, 63: 200–211.
Morgan, S.G.McMahon, M.Mitton, C.Roughead, E.Kirk, R.Kanavos, P., and Menon, D. (2006a), Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom: Well-designed processes can help policymakers make tough, evidence based decisions, Health Affairs, 25(2): 337–347.
Morgan, S.McMahon, M., and Mitton, C. (2006b), Centralising drug review to improve coverage decisions: economic lessons from (and for) Canada, Applied Health Economics and Health Policy, 5(2): 67–73.
Persson, U. and Hjelmgren, J. (2003), Hälso- och sjukvården behöver kunskap om hur befolkningen värderar hälsa’ (Information of the public assessment of the value of health is needed in health care), Läkartidningen, 43(100): 3436–3437.
Pope, C.Ziebland, S., and Mays, N. (2000), Qualitative research in health care: analysing qualitative data, British Medical Journal, 320: 114–116.
Ramsberg, J.Lundin, D.Engström, A., and Jacob, J. (2004), ‘How drugs for rare diseases are and should be treated in pricing and reimbursement’, Paper presented at the 5th International Conference on Priorities in Health Care, 3–5 November, Wellington, New Zealand.
Singer, P.A.Martin, D.K.Giacomini, M., and Purdy, L. (2000), Priority setting for new technologies in medicine: qualitative case study, British Medial Journal, 321: 1316–1318.
Towse, A. and Pritchard, C. (2002), National Institute for clinical Excellence (NICE): is economic appraisal working?, Pharmacoeconomics, 20(Suppl. 3): 95–105.
Yin, R. K. (2003), Case study research: Design and Methods, third edition, Applied Social Research Methods Series, vol. 5, London: Sage Publications.